Formulary Group work programme


The Group meets monthly on the third Tuesday of each month. The following list notes medicines that will be scheduled for review in the next three to four months. This list is indicative and may be subject to change.

Bevacizumab (Avastin®) - SMC 1135/16 - in progress. (Indication: for use in combination with paclitaxel and cisplatin in patients who cannot receive platinum therapy, for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix).

Bortezomib (Velcade®) - SMC 1075/16 - in progress (Indication: for use in combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation).

Brivaracetam (Briviact®) - SMC 1160/16 - Formulary Group decision will be published by 3rd August 2016. (Indication: Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy).

Co-careldopa (Duodopa®) - SMC 316/06 - in progress. (Indication: for the treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results).

Crizotinib (Xalkori®) - SMC 1152/16 - Formulary Group decision will be published by 3rd August 2016. (Indication:  for first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)).

Naloxegol (Moventig®) - SMC 1106/15 - Formulary Group decision will be published by 3rd August 2016. (Indication: for the treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxative(s)).

Nivolumab (Opdivo®) - SMC 1144/16 - Formulary Group decision will be published by 3rd August 2016. (Indication: for the reatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults).

Ofatumumab (Arzerra®) - SMC 1037/15 -  In progress. (Indication: for the use of ofatumumab in combination with chlorambucil or bendamustine is indicated for the treatment of patients with chronic lymphocytic leukaemia (CLL) who have not received prior therapy and who are not eligible for fludarabine-based therapy).

Panobinostat (Farydak®) - SMC 1122/16 - In progress. (Indication: In combination with bortezomib and dexamethasone, for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent).

Regorafenib (Stivarga®) - SMC 1031/15 - in progress. (Indication: for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib).

Secukinumab (Cosentyx®) - SMC 1159/16 - in progress. (Indication: for the treatment of active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy).

Sorafenib (Nexavar®) - SMC 482/08 - in progress (Indication: for the treatment of hepatocellular carcinoma).

Trastuzumab (Herceptin®) - SMC 623/10 - in progress. (Indication: in combination with capecitabine or fluorouracil and cisplatin for the treatment of patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.  It is indicated for use only in patients with metastatic gastric cancer whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory FISH+ result, or IHC 3+, as determined by an accurate and validated assay).

Ulipristal acetate (Esmya®) - SMC 1128/16 - Formulary Group decision will be published by 3rd August 2016. (Indication: for the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age).

Vortioxetine (Brintellix®) - SMC 1158/16 - Formulary Group decision will be published by 3rd August 2016. (Indication: for the treatment of major depressive episodes in adults).

Publication schedule

This web page is updated monthly, within 7 working days of publication of SMC advice.

END